Axsome Therapeutics, Inc. (AXSM) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Axsome Therapeutics, Inc.'s filing signal turned positive.

Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on developing and commercializing innovative medicines for central nervous system (CNS) conditions. The company's portfolio includes three FDA-approved commercial products: AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for acute migraine. In 2025, total revenues from these products reached $638.5 million, marking a 66% annual increase. Axsome is also advancing a deep pipeline of novel product candidates, including AXS-05 for Alzheimer's disease agitation and smoking cessation, and solriamfetol for ADHD and other sleep-related disorders. The company's strategy centers on addressing high unmet medical needs in CNS disorders through proprietary medicinal chemistry and formulation technologies, aiming to develop differentiated therapies.

Revenue is primarily driven by sales of its commercial products: AUVELITY, SUNOSI, and SYMBRAVO. The company also generates royalty revenue from out-licensed territories for SUNOSI.